^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ASP1570

    i
    Other names: ASP1570, ASP-1570, ASP 1570
    Associations

    News

    Trials
    Company:
    Astellas
    Drug class:
    DGKZ inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase Zeta Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer. (PubMed, Mol Cancer Ther)
    The antitumor efficacy of ASP1570 was cancelled by CD8+ T-cell depletion, indicating that its antitumor effect depends on CD8+ cytotoxic T-cell activation. Collectively, ASP1570 potentially improves antitumor efficacy in both anti-PD-1-therapy-resistant and anti-PD-1-therapy-responsive tumors by overcoming multiple immunosuppressive signals.
    Journal
    |
    CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • TGFB1 (Transforming Growth Factor Beta 1) • DGKZ (Diacylglycerol Kinase Zeta)
    |
    ASP1570
    1year
    KEYNOTE-E59: A Study of ASP1570 Alone or in Combination With Pembrolizumab or Standard Therapies in Adults With Solid Tumors (clinicaltrials.gov)
    P1/2; Trial completion date: Dec 2027 --> May 2028 | Trial primary completion date: Dec 2027 --> May 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • docetaxel • Lonsurf (trifluridine/tipiracil) • ASP1570
    almost2years
    KEYNOTE-E59: A Study of ASP1570 Taken by Itself or With Pembrolizumab in Adults With Solid Tumors (clinicaltrials.gov)
    P1/2; Trial completion date: Apr 2027 --> Dec 2027 | Trial primary completion date: Apr 2027 --> Dec 2027
    Combination therapy • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • EGFR mutation • ALK positive • ALK mutation • NTRK fusion
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • ASP1570
    over2years
    The diacylglycerol kinase ζ inhibitor ASP1570 augments natural killer cell function. (PubMed, Int Immunopharmacol)
    Accordingly, ASP1570 treatment enhanced IFNγ production and degranulation of immunoreceptor-activated NK cells in vitro and NK cell-mediated tumor clearance in vivo. Thus, ASP1570 enhances both T and NK cell function, which could possibly induce more durable anti-tumor responses for immunotherapy.
    Journal
    |
    IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    ASP1570
    3years
    A Study of ASP1570 Taken by Itself or With Pembrolizumab in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2; N=168 --> 266
    Combination therapy • Enrollment change • Metastases
    |
    EGFR (Epidermal growth factor receptor) • CD4 (CD4 Molecule) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • EGFR mutation • ALK positive • ALK mutation • NTRK fusion
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • ASP1570
    over3years
    A Study of ASP1570 in Adults With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=168, Recruiting, Astellas Pharma Global Development, Inc. | Phase classification: P1 --> P1/2 | Trial completion date: Aug 2026 --> Apr 2027 | Trial primary completion date: Aug 2026 --> Apr 2027
    Phase classification • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • CD4 (CD4 Molecule) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    ASP1570
    almost4years
    A Study of ASP1570 in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=138, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: May 2024 --> Jul 2026 | Trial primary completion date: May 2024 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • CD4 (CD4 Molecule)
    |
    ALK positive • ALK mutation
    |
    ASP1570
    over4years
    A Study of ASP1570 in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=138, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting | Trial completion date: Oct 2023 --> May 2024 | Trial primary completion date: Aug 2023 --> May 2024
    Enrollment open • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • CD4 (CD4 Molecule)
    |
    ALK positive • ALK mutation
    |
    ASP1570
    over4years
    A Study of ASP1570 in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=138, Not yet recruiting, Astellas Pharma Global Development, Inc.
    Clinical • New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • CD4 (CD4 Molecule)
    |
    ALK positive • ALK mutation
    |
    ASP1570